Strain Name:

B6;129S7-Bdkrb2tm1Jfh/J

Stock Number:

002641

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Other products are available, see Purchasing Information for Cryopreserved Embryos

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Mutant Stock; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
 
Donating InvestigatorDr. J. F Hess,   Merck Research Laboratories

Description
Mice homozygous for the Bdkrb2tm1Jfh targeted mutation are viable and fertile and display no major defects. Homozygous mutant tissue from the ileum, uterus, and superior cervical ganglia all failed to respond to pharmacological doses of bradykinin. This finding supports the existance of only one type of B2 receptor. B2 deficient mice also display a greater hypertensive response to chronic high sodium intake compared to controls. These mice may be used to study the role of the B2 receptor in hypertension, inflammation, the cardiovascular system, renal function and reproduction.

Control Information

  Control
   101045 B6129SF2/J (approximate)
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Bdkrb2tm1Jfh allele
006860   B6.Cg-Ins2Akita Bdkrb2tm1Jfh/SmiJ
View Strains carrying   Bdkrb2tm1Jfh     (1 strain)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Bdkrb2tm1Jfh/Bdkrb2tm1Jfh

        involves: 129S7/SvEvBrd * C57BL/6
  • normal phenotype
  • no abnormal phenotype detected
    • mice are viable and fertile; no metabolic, pathological or histopathological abnormalities were detected   (MGI Ref ID J:25953)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Bdkrb2tm1Jfh/Bdkrb2tm1Jfh

        B6.129S7-Bdkrb2tm1Jfh
  • mortality/aging
  • increased sensitivity to induced morbidity/mortality
    • increased mortality following renal ischemia/reperfusion procedure (1 of 8) compared to wild-type (0 of 10) and sham controls (0 of 7)   (MGI Ref ID J:121339)
  • partial postnatal lethality
    • following embryonic salt stress (high-salt, 5% NaCl intake), only 38% of progeny from heterozygous matings survive past the first week of life, unlike in unstressed homozygotes or salt-loaded wild-type control mice where survival is 84% or greater   (MGI Ref ID J:65386)
  • premature death
    • mice have much shorter lifespan than wild-type; 909 days (wt) vs 755 days (mutant)   (MGI Ref ID J:108948)
  • renal/urinary system phenotype
  • *normal* renal/urinary system phenotype
    • under physiological conditions, 8-wk-old male homozygotes exhibit normal kidney weight, renal plasma flow, glomerular filtration rate (GFR), renal vascular resistance (RVR), urine osmolarity, and urine sodium and potassium excretion relative to wild-type controls   (MGI Ref ID J:83895)
    • abnormal kidney morphology
      • in the kidney of postischimic mice there is more oxidative nuclear and mitochondrial DNA modification than in wild-type but not as severe as in the Bdkrb1/Bdkrb2 double knockout   (MGI Ref ID J:121339)
      • apoptosis rates are increased in postischemic mice compared to in wild-type but not as much as in the Bdkrb1/Bdkrb2 double knockout   (MGI Ref ID J:121339)
      • abnormal kidney cortex morphology
        • at P2, salt-stressed homozygotes display a disorganized renal cortex   (MGI Ref ID J:65386)
        • abnormal juxtaglomerular apparatus morphology
          • the % of juxtaglomerular apparatuses expressing rennin is significantly lower than in homozygotes maintained on normal salt intake   (MGI Ref ID J:65386)
          • abnormal juxtaglomerular cell morphology
            • at P2, salt-stressed homozygotes display suppressed immunoreactive renin in juxtaglomerular cells   (MGI Ref ID J:65386)
        • abnormal kidney medullary ray morphology
          • at P2, the cortical medullary rays are either poorly developed or missing in salt-stressed mutants, unlike in control mice   (MGI Ref ID J:65386)
        • abnormal renal glomerulus morphology
          • at P2, salt-stressed homozygotes display primitive glomeruli, unlike control mice; however, the number of mature glomeruli and glomerular generations remain normal   (MGI Ref ID J:65386)
          • abnormal glomerular capillary morphology
            • under physiological conditions, 8-wk-old male homozygotes show a reduced glomerular tuft area, caused by a ~20% reduction in glomerular capillary surface area relative to wild-type controls   (MGI Ref ID J:83895)
        • increased glomerular capsule space
          • salt-stressed homozygotes display dilated Bowman's space, unlike control mice   (MGI Ref ID J:65386)
        • kidney cortex cysts
          • at P2, salt-stressed homozygotes display areas of tubular microcysts   (MGI Ref ID J:65386)
      • abnormal kidney development
        • following embryonic salt stress, E16 homozygotes display abnormal nephrogenesis with focal areas of tubular ectasia   (MGI Ref ID J:65386)
      • abnormal nephron morphology
        • at P2, salt-stressed homozygotes display renal dysplasia in the distal nephron, unlike control mice   (MGI Ref ID J:65386)
        • increased susceptibility to salt-induced nephropathy is intrinsic to the fetus; homozygous offspring from heterozygous parents display the same renal phenotype as offspring from homozygous null parents   (MGI Ref ID J:65386)
        • chronic antihypertensive therapy (hydralazine; birth to P20) does not modify the severity of renal defects   (MGI Ref ID J:65386)
        • a significantly higher % of homozygotes develop salt-induced renal abnormalities on a congenic C57BL/6J background (84%) compared to a mixed 129 x C57BL/6 (F4) genetic background (57%)   (MGI Ref ID J:65386)
        • abnormal renal glomerulus morphology
          • at P2, salt-stressed homozygotes display primitive glomeruli, unlike control mice; however, the number of mature glomeruli and glomerular generations remain normal   (MGI Ref ID J:65386)
          • abnormal glomerular capillary morphology
            • under physiological conditions, 8-wk-old male homozygotes show a reduced glomerular tuft area, caused by a ~20% reduction in glomerular capillary surface area relative to wild-type controls   (MGI Ref ID J:83895)
        • abnormal renal tubule morphology
          • at P2, salt-stressed homozygotes display renal tubule dysplasia of ureteric bud origin   (MGI Ref ID J:65386)
          • abnormal proximal convoluted tubule morphology
            • postischimic mice have more severe histologial changes in renal proximal tubules than in wild-type but not as severe as in the double knockout   (MGI Ref ID J:121339)
          • abnormal renal tubule epithelium morphology
            • at P2, salt-stressed homozygotes display aberrations in epithelial nephrogenesis involving both kidneys   (MGI Ref ID J:65386)
          • dilated renal tubules
            • at P2, salt-stressed homozygotes display tubular ectasia   (MGI Ref ID J:65386)
        • increased glomerular capsule space
          • salt-stressed homozygotes display dilated Bowman's space, unlike control mice   (MGI Ref ID J:65386)
    • abnormal kidney physiology
      • 8-wk-old male homozygotes show a 50% decrease in basal cGMP levels in isolated glomeruli relative to wild-type controls   (MGI Ref ID J:83895)
      • following stimulation with calcium ionophore A23187, mutant glomeruli exhibit a significantly lower cGMP production relative to wild-type controls, suggesting an impaired NO-cGMP pathway   (MGI Ref ID J:83895)
    • decreased urine nitrite level
      • under physiological conditions, 8-wk-old male homozygotes display significantly reduced nitrite excretion relative to wild-type controls   (MGI Ref ID J:83895)
  • homeostasis/metabolism phenotype
  • *normal* homeostasis/metabolism phenotype
    • under physiological conditions, 8-wk-old male homozygotes display normal urine osmolarity, and urine sodium and potassium excretion relative to wild-type controls   (MGI Ref ID J:83895)
    • decreased blood urea nitrogen level
      • fasting plasma nitrite/nitrate levels are decreased compared to normal   (MGI Ref ID J:121339)
    • decreased urine nitrite level
      • under physiological conditions, 8-wk-old male homozygotes display significantly reduced nitrite excretion relative to wild-type controls   (MGI Ref ID J:83895)
    • increased blood urea nitrogen level
      • postischimic mice have increased plasma urea nitrogen compared to wild-type but not as much as in the Bdkrb1/Bdkrb2 double knockout   (MGI Ref ID J:121339)
    • increased circulating creatinine level
      • postischimic mice have increased plasma creatinine compared to wild-type but not as much as in the Bdkrb1/Bdkrb2 double knockout   (MGI Ref ID J:121339)
  • cellular phenotype
  • abnormal mitochondrial chromosome morphology
    • mutant mice show greater mitochondrial damage than wild-type at 12 months of age   (MGI Ref ID J:108948)
  • endocrine/exocrine gland phenotype
  • abnormal Leydig cell morphology
    • mutant males display some pigmented vacuoles in Leydig cells in the testes at 12 months of age   (MGI Ref ID J:108948)
  • reproductive system phenotype
  • abnormal Leydig cell morphology
    • mutant males display some pigmented vacuoles in Leydig cells in the testes at 12 months of age   (MGI Ref ID J:108948)
  • skeleton phenotype
  • decreased bone mineral density
    • mutants have significantly reduced bone density compared to wild-type   (MGI Ref ID J:108948)
  • behavior/neurological phenotype
  • *normal* behavior/neurological phenotype
    • under physiological conditions, 8-wk-old male homozygotes exhibit normal water and food intake relative to wild-type controls   (MGI Ref ID J:83895)
  • cardiovascular system phenotype
  • *normal* cardiovascular system phenotype
    • under physiological conditions, 8-wk-old male homozygotes display normal blood pressure, heart rate, renal plasma flow, and renal vascular resistance relative to wild-type controls   (MGI Ref ID J:83895)
    • abnormal glomerular capillary morphology
      • under physiological conditions, 8-wk-old male homozygotes show a reduced glomerular tuft area, caused by a ~20% reduction in glomerular capillary surface area relative to wild-type controls   (MGI Ref ID J:83895)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Bdkrb2tm1Jfh related

Cardiovascular Research
Hypertension
      diet-induced

Immunology, Inflammation and Autoimmunity Research
Inflammation

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Bdkrb2tm1Jfh
Allele Name targeted mutation 1, J Fred Hess
Allele Type Targeted (Null/Knockout)
Common Name(s) B2-; B2-KO; B2R-; BdkrB2; Bk B2R-; Bk2r-; rB2 -;
Mutation Made ByDr. J. Hess,   Merck Research Laboratories
Strain of Origin129S7/SvEvBrd-Hprt
ES Cell Line NameAB2.1
ES Cell Line Strain129S7/SvEvBrd-Hprt
Gene Symbol and Name Bdkrb2, bradykinin receptor, beta 2
Chromosome 12
Gene Common Name(s) B(2); B2; B2BKR; B2BRA; B2R; BK-2; BK2; BK2R; BKR2; BRB2; kinin B2;
Molecular Note A neomycin selection cassette replaced the entire coding sequences of the gene. Binding assays on membranes prepared from ileum tissue of homozygous mice confirmed that no functional protein is produced from this allele. [MGI Ref ID J:25953]

Genotyping

Genotyping Information

Genotyping Protocols

Bdkrb2tm1Jfh,

MELT


Bdkrb2tm1Jfh, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Borkowski JA; Ransom RW; Seabrook GR; Trumbauer M; Chen H; Hill RG; Strader CD; Hess JF. 1995. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270(23):13706-10. [PubMed: 7775424]  [MGI Ref ID J:25953]

Additional References

Alfie ME; Yang XP; Hess F; Carretero OA. 1996. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224(3):625-30. [PubMed: 8713099]  [MGI Ref ID J:34497]

Borkowski JA; Hess JF. 1995. Targeted disruption of the mouse B2 bradykinin receptor in embryonic stem cells. Can J Physiol Pharmacol 73(7):773-9. [PubMed: 8846408]  [MGI Ref ID J:29827]

Rupniak NM; Boyce S; Webb JK; Williams AR; Carlson EJ; Hill RG ; Borkowski JA ; Hess JF. 1997. Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 71(1):89-97. [PubMed: 9200178]  [MGI Ref ID J:41328]

Yosipiv IV; Dipp S; El-Dahr SS. 2001. Targeted disruption of the bradykinin B(2) receptor gene in mice alters the ontogeny of the renin-angiotensin system. Am J Physiol Renal Physiol 281(5):F795-801. [PubMed: 11592936]  [MGI Ref ID J:72552]

Bdkrb2tm1Jfh related

Abadir PM; Carey RM; Siragy HM. 2003. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42(4):600-4. [PubMed: 12953015]  [MGI Ref ID J:103114]

Adolfo Arganaraz G; Regina Perosa S; Cristina Lencioni E; Bader M; Abrao Cavalheiro E; da Graca Naffah-Mazzacoratti M; Bosco Pesquero J; Antonio Silva J Jr. 2004. Role of kinin B1 and B2 receptors in the development of pilocarpine model of epilepsy. Brain Res 1013(1):30-9. [PubMed: 15196965]  [MGI Ref ID J:90943]

Alfie ME; Alim S; Mehta D; Shesely EG; Carretero OA. 1999. An enhanced effect of arginine vasopressin in bradykinin B2 receptor null mutant mice. Hypertension 33(6):1436-40. [PubMed: 10373229]  [MGI Ref ID J:56192]

Alfie ME; Yang XP; Hess F; Carretero OA. 1996. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224(3):625-30. [PubMed: 8713099]  [MGI Ref ID J:34497]

Aliberti J; Viola JP; Vieira-de-Abreu A; Bozza PT; Sher A; Scharfstein J. 2003. Cutting edge: Bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 170(11):5349-53. [PubMed: 12759407]  [MGI Ref ID J:83453]

Barros CC; Haro A; Russo FJ; Schadock I; Almeida SS; Reis FC; Moraes MR; Haidar A; Hirata AE; Mori M; Bacurau RF; Wurtele M; Bader M; Pesquero JB; Araujo RC. 2012. Bradykinin inhibits hepatic gluconeogenesis in obese mice. Lab Invest 92(10):1419-27. [PubMed: 22868909]  [MGI Ref ID J:188609]

Bergaya S; Meneton P; Bloch-Faure M; Mathieu E; Alhenc-Gelas F; Levy BI; Boulanger CM. 2001. Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88(6):593-9. [PubMed: 11282893]  [MGI Ref ID J:115590]

Bernstein KE; Xiao HD; Frenzel K; Li P; Shen XZ; Adams JW; Fuchs S. 2005. Six truisms concerning ACE and the renin-angiotensin system educed from the genetic analysis of mice. Circ Res 96(11):1135-44. [PubMed: 15947253]  [MGI Ref ID J:109628]

Bhagat TD; Zhou L; Sokol L; Kessel R; Caceres G; Gundabolu K; Tamari R; Gordon S; Mantzaris I; Jodlowski T; Yu Y; Jing X; Polineni R; Bhatia K; Pellagatti A; Boultwood J; Kambhampati S; Steidl U; Stein C; Ju W; Liu G; Kenny P; List A; Bitzer M; Verma A. 2013. miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling. Blood 121(15):2875-81. [PubMed: 23390194]  [MGI Ref ID J:196470]

Blaes N; Pecher C; Mehrenberger M; Cellier E; Praddaude F; Chevalier J; Tack I; Couture R; Girolami JP. 2012. Bradykinin inhibits high glucose- and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor. Am J Physiol Renal Physiol 303(2):F293-303. [PubMed: 22573379]  [MGI Ref ID J:187019]

Brochu I; Labonte J; Bkaily G; D'Orleans-Juste P. 2002. Role of endothelin receptors in the hypertensive state of kinin B(2) knockout mice subjected to a high-salt diet. Clin Sci (Lond) 103 Suppl 48:380S-384S. [PubMed: 12193127]  [MGI Ref ID J:103135]

Cervenka L; Harrison-Bernard LM; Dipp S; Primrose G; Imig JD; El-Dahr SS. 1999. Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. Hypertension 34(2):176-80. [PubMed: 10454437]  [MGI Ref ID J:88466]

Cervenka L; Vaneckova I; Maly J; Horacek V; El-Dahr SS. 2003. Genetic inactivation of the B2 receptor in mice worsens two-kidney, one-clip hypertension: role of NO and the AT2 receptor. J Hypertens 21(8):1531-8. [PubMed: 12872048]  [MGI Ref ID J:106003]

Diehl SA; McElvany B; Noubade R; Seeberger N; Harding B; Spach K; Teuscher C. 2014. G proteins Galphai1/3 are critical targets for Bordetella pertussis toxin-induced vasoactive amine sensitization. Infect Immun 82(2):773-82. [PubMed: 24478091]  [MGI Ref ID J:209809]

Duka I; Kintsurashvili E; Gavras I; Johns C; Bresnahan M; Gavras H. 2001. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 88(3):275-81. [PubMed: 11179194]  [MGI Ref ID J:115601]

Duka I; Shenouda S; Johns C; Kintsurashvili E; Gavras I; Gavras H. 2001. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 38(6):1355-60. [PubMed: 11751717]  [MGI Ref ID J:103241]

Dutra RC; Bento AF; Leite DF; Manjavachi MN; Marcon R; Bicca MA; Pesquero JB; Calixto JB. 2013. The role of kinin B1 and B2 receptors in the persistent pain induced by experimental autoimmune encephalomyelitis (EAE) in mice: evidence for the involvement of astrocytes. Neurobiol Dis 54:82-93. [PubMed: 23454198]  [MGI Ref ID J:197950]

Dutra RC; Leite DF; Bento AF; Manjavachi MN; Patricio ES; Figueiredo CP; Pesquero JB; Calixto JB. 2011. The role of kinin receptors in preventing neuroinflammation and its clinical severity during experimental autoimmune encephalomyelitis in mice. PLoS One 6(11):e27875. [PubMed: 22132157]  [MGI Ref ID J:201039]

El-Dahr SS; Aboudehen K; Dipp S. 2008. Bradykinin B2 receptor null mice harboring a Ser23-to-Ala substitution in the p53 gene are protected from renal dysgenesis. Am J Physiol Renal Physiol 295(5):F1404-13. [PubMed: 18753293]  [MGI Ref ID J:140998]

El-Dahr SS; Harrison-Bernard LM; Dipp S; Yosipiv IV; Meleg-Smith S. 2000. Bradykinin B2 null mice are prone to renal dysplasia: gene-environment interactions in kidney development Physiol Genomics 3(3):121-31. [PubMed: 11015607]  [MGI Ref ID J:65386]

Emanueli C; Fink E; Milia AF; Salis MB; Conti M; Demontis MP; Madeddu P. 1998. Enhanced blood pressure sensitivity to deoxycorticosterone in mice with disruption of bradykinin B2 receptor gene. Hypertension 31(6):1278-83. [PubMed: 9622142]  [MGI Ref ID J:48384]

Emanueli C; Maestri R; Corradi D; Marchione R; Minasi A; Tozzi MG; Salis MB; Straino S; Capogrossi MC; Olivetti G; Madeddu P. 1999. Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice [see comments] Circulation 100(23):2359-65. [PubMed: 10587341]  [MGI Ref ID J:59835]

Fan H; Harrell JR; Dipp S; Saifudeen Z; El-Dahr SS. 2005. A novel pathological role of p53 in kidney development revealed by gene-environment interactions. Am J Physiol Renal Physiol 288(1):F98-107. [PubMed: 15383401]  [MGI Ref ID J:104678]

Fan H; Stefkova J; El-Dahr SS. 2006. Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway. Am J Physiol Renal Physiol 291(3):F670-82. [PubMed: 16571598]  [MGI Ref ID J:111678]

Fang C; Stavrou E; Schmaier AA; Grobe N; Morris M; Chen A; Nieman MT; Adams GN; LaRusch G; Zhou Y; Bilodeau ML; Mahdi F; Warnock M; Schmaier AH. 2013. Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. Blood 121(15):3023-32. [PubMed: 23386129]  [MGI Ref ID J:196472]

Ferreira J; Campos MM; Pesquero JB; Araujo RC; Bader M; Calixto JB. 2001. Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology 41(8):1006-12. [PubMed: 11747905]  [MGI Ref ID J:179423]

Han ED; MacFarlane RC; Mulligan AN; Scafidi J; Davis AE 3rd. 2002. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109(8):1057-63. [PubMed: 11956243]  [MGI Ref ID J:76090]

Harrison-Bernard LM; Dipp S; El-Dahr SS. 2003. Renal and blood pressure phenotype in 18-mo-old bradykinin B2R(-/-)CRD mice. Am J Physiol Regul Integr Comp Physiol 285(4):R782-90. [PubMed: 12805091]  [MGI Ref ID J:84494]

Hess JF; Chen RZ; Hey P; Breese R; Chang RS; Chen TB; Bock MG; Vogt T; Pettibone DJ. 2006. Generation and characterization of a humanized bradykinin B1 receptor mouse. Biol Chem 387(2):195-201. [PubMed: 16497152]  [MGI Ref ID J:135789]

Hillmeister P; Gatzke N; Dulsner A; Bader M; Schadock I; Hoefer I; Hamann I; Infante-Duarte C; Jung G; Troidl K; Urban D; Stawowy P; Frentsch M; Li M; Nagorka S; Wang H; Shi Y; le Noble F; Buschmann I. 2011. Arteriogenesis is modulated by bradykinin receptor signaling. Circ Res 109(5):524-33. [PubMed: 21719759]  [MGI Ref ID J:186598]

Isbell DC; Voros S; Yang Z; DiMaria JM; Berr SS; French BA; Epstein FH; Bishop SP; Wang H; Roy RJ; Kemp BA; Matsubara H; Carey RM; Kramer CM. 2007. Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling. Am J Physiol Heart Circ Physiol 293(6):H3372-8. [PubMed: 17933966]  [MGI Ref ID J:132208]

Jaffa MA; Kobeissy F; Al Hariri M; Chalhoub H; Eid A; Ziyadeh FN; Jaffa AA. 2012. Global renal gene expression profiling analysis in B2-kinin receptor null mice: impact of diabetes. PLoS One 7(9):e44714. [PubMed: 23028588]  [MGI Ref ID J:191871]

Kahn R; Hellmark T; Leeb-Lundberg LM; Akbari N; Todiras M; Olofsson T; Wieslander J; Christensson A; Westman K; Bader M; Muller-Esterl W; Karpman D. 2009. Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. J Immunol 182(12):7906-15. [PubMed: 19494315]  [MGI Ref ID J:149285]

Kakoki M; Kizer CM; Yi X; Takahashi N; Kim HS; Bagnell CR; Edgell CJ; Maeda N; Jennette JC; Smithies O. 2006. Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 116(5):1302-9. [PubMed: 16604193]  [MGI Ref ID J:108948]

Kakoki M; McGarrah RW; Kim HS; Smithies O. 2007. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 104(18):7576-81. [PubMed: 17452647]  [MGI Ref ID J:121339]

Kakoki M; Sullivan KA; Backus C; Hayes JM; Oh SS; Hua K; Gasim AM; Tomita H; Grant R; Nossov SB; Kim HS; Jennette JC; Feldman EL; Smithies O. 2010. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A 107(22):10190-5. [PubMed: 20479236]  [MGI Ref ID J:161075]

Kakoki M; Takahashi N; Jennette JC; Smithies O. 2004. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A 101(36):13302-5. [PubMed: 15326315]  [MGI Ref ID J:92403]

Krankel N; Kuschnerus K; Muller M; Speer T; Mocharla P; Madeddu P; Bader M; Luscher TF; Landmesser U. 2013. Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease. Circulation 127(5):594-603. [PubMed: 23275384]  [MGI Ref ID J:210277]

Lu F; Chauhan AK; Fernandes SM; Walsh MT; Wagner DD; Davis AE 3rd. 2008. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol 295(5):G1042-9. [PubMed: 18787060]  [MGI Ref ID J:142529]

Madeddu P; Emanueli C; Gaspa L; Salis B; Milia AF; Chao L; Chao J. 1999. Role of the bradykinin B2 receptor in the maturation of blood pressure phenotype: lesson from transgenic and knockout mice Immunopharmacology 44(1-2):9-13. [PubMed: 10604518]  [MGI Ref ID J:59794]

Madeddu P; Emanueli C; Maestri R; Salis MB; Minasi A; Capogrossi MC; Olivetti G. 2000. Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice Hypertension 35(1 Pt 2):391-6. [PubMed: 10642330]  [MGI Ref ID J:60047]

Madeddu P; Salis MB; Emanueli C. 1999. Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice Immunopharmacology 45(1-3):21-7. [PubMed: 10614985]  [MGI Ref ID J:59776]

Madeddu P; Varoni MV; Palomba D; Emanueli C; Demontis MP; Glorioso N; Dessi-Fulgheri P; Sarzani R; Anania V. 1997. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96(10):3570-8. [PubMed: 9396457]  [MGI Ref ID J:112265]

Maestri R; Milia AF; Salis MB; Graiani G; Lagrasta C; Monica M; Corradi D; Emanueli C; Madeddu P. 2003. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 41(5):1151-5. [PubMed: 12654715]  [MGI Ref ID J:103026]

Maul B; Krause W; Pankow K; Becker M; Gembardt F; Alenina N; Walther T; Bader M; Siems WE. 2005. Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J 19(11):1474-81. [PubMed: 16126915]  [MGI Ref ID J:101196]

Milia AF; Gross V; Plehm R; De Silva JA Jr; Bader M; Luft FC. 2001. Normal blood pressure and renal function in mice lacking the bradykinin B(2) receptor. Hypertension 37(6):1473-9. [PubMed: 11408397]  [MGI Ref ID J:103234]

Monteiro AC; Schmitz V; Svensjo E; Gazzinelli RT; Almeida IC; Todorov A; de Arruda LB; Torrecilhas AC; Pesquero JB; Morrot A; Bouskela E; Bonomo A; Lima AP; Muller-Esterl W; Scharfstein J. 2006. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi. J Immunol 177(9):6325-35. [PubMed: 17056563]  [MGI Ref ID J:140513]

Picard N; Eladari D; El Moghrabi S; Planes C; Bourgeois S; Houillier P; Wang Q; Burnier M; Deschenes G; Knepper MA; Meneton P; Chambrey R. 2008. Defective ENaC processing and function in tissue kallikrein-deficient mice. J Biol Chem 283(8):4602-11. [PubMed: 18086683]  [MGI Ref ID J:132178]

Prediger RD; Medeiros R; Pandolfo P; Duarte FS; Passos GF; Pesquero JB; Campos MM; Calixto JB; Takahashi RN. 2008. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease. Neuroscience 151(3):631-43. [PubMed: 18191900]  [MGI Ref ID J:135258]

Rhaleb NE; Peng H; Alfie ME; Shesely EG; Carretero OA. 1999. Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role? Hypertension 33(1 Pt 2):329-34. [PubMed: 9931125]  [MGI Ref ID J:53680]

Rodi D; Buzzi A; Barbieri M; Zucchini S; Verlengia G; Binaschi A; Regoli D; Boschi A; Ongali B; Couture R; Simonato M. 2013. Bradykinin B receptors increase hippocampal excitability and susceptibility to seizures in mice. Neuroscience 248C:392-402. [PubMed: 23811399]  [MGI Ref ID J:207053]

Rodrigues ES; Martin RP; Felipe SA; Bader M; Oliveira SM; Shimuta SI. 2009. Cross talk between kinin and angiotensin II receptors in mouse abdominal aorta. Biol Chem 390(9):907-13. [PubMed: 19453270]  [MGI Ref ID J:164962]

Rupniak NM; Boyce S; Webb JK; Williams AR; Carlson EJ; Hill RG ; Borkowski JA ; Hess JF. 1997. Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain 71(1):89-97. [PubMed: 9200178]  [MGI Ref ID J:41328]

Sanchez de Miguel L; Neysari S; Jakob S; Petrimpol M; Butz N; Banfi A; Zaugg CE; Humar R; Battegay EJ. 2008. B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart. Cardiovasc Res 80(1):106-13. [PubMed: 18566101]  [MGI Ref ID J:161893]

Schanstra JP; Bachvarova M; Neau E; Bascands JL; Bachvarov D. 2007. Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Kidney Int 72(4):442-54. [PubMed: 17579666]  [MGI Ref ID J:152886]

Schanstra JP; Duchene J; Praddaude F; Bruneval P; Tack I; Chevalier J; Girolami JP; Bascands JL. 2003. Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284(6):H1904-8. [PubMed: 12560214]  [MGI Ref ID J:83895]

Schanstra JP; Neau E; Drogoz P; Arevalo Gomez MA; Lopez Novoa JM; Calise D; Pecher C; Bader M; Girolami JP; Bascands JL. 2002. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110(3):371-9. [PubMed: 12163456]  [MGI Ref ID J:78354]

Shariat-Madar Z; Mahdi F; Warnock M; Homeister JW; Srikanth S; Krijanovski Y; Murphey LJ; Jaffa AA; Schmaier AH. 2006. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108(1):192-9. [PubMed: 16514058]  [MGI Ref ID J:135575]

Silvestre JS; Bergaya S; Tamarat R; Duriez M; Boulanger CM; Levy BI. 2001. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 89(8):678-83. [PubMed: 11597990]  [MGI Ref ID J:115630]

Song JJ; Hwang I; Cho KH; Garcia MA; Kim AJ; Wang TH; Lindstrom TM; Lee AT; Nishimura T; Zhao L; Morser J; Nesheim M; Goodman SB; Lee DM; Bridges SL Jr; Gregersen PK; Leung LL; Robinson WH. 2011. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 121(9):3517-27. [PubMed: 21804193]  [MGI Ref ID J:178261]

Strecker T; Messlinger K; Weyand M; Reeh PW. 2005. Role of different proton-sensitive channels in releasing calcitonin gene-related peptide from isolated hearts of mutant mice. Cardiovasc Res 65(2):405-10. [PubMed: 15639479]  [MGI Ref ID J:101967]

Tan Y; Keum JS; Wang B; McHenry MB; Lipsitz SR; Jaffa AA. 2007. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 293(4):F1026-35. [PubMed: 17596525]  [MGI Ref ID J:142936]

Trabold F; Pons S; Hagege AA; Bloch-Faure M; Alhenc-Gelas F; Giudicelli JF; Richer-Giudicelli C; Meneton P. 2002. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 40(1):90-5. [PubMed: 12105144]  [MGI Ref ID J:103162]

Trevisani M; Schmidlin F; Tognetto M; Nijkamp FP; Gies JP; Frossard N; Amadesi S; Folkerts G; Geppetti P. 1999. Evidence for in vitro expression of B1 receptor in the mouse trachea and urinary bladder. Br J Pharmacol 126(6):1293-300. [PubMed: 10217521]  [MGI Ref ID J:54390]

Vashistha H; Singhal PC; Malhotra A; Husain M; Mathieson P; Saleem MA; Kuriakose C; Seshan S; Wilk A; Delvalle L; Peruzzi F; Giorgio M; Pelicci PG; Smithies O; Kim HS; Kakoki M; Reiss K; Meggs LG. 2012. Null mutations at the p66 and bradykinin 2 receptor loci induce divergent phenotypes in the diabetic kidney. Am J Physiol Renal Physiol 303(12):F1629-40. [PubMed: 23019230]  [MGI Ref ID J:190320]

Wang H; Kohno T; Amaya F; Brenner GJ; Ito N; Allchorne A; Ji RR; Woolf CJ. 2005. Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci 25(35):7986-92. [PubMed: 16135755]  [MGI Ref ID J:100473]

Xi L; Das A; Zhao ZQ; Merino VF; Bader M; Kukreja RC. 2008. Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation 118(14 Suppl):S32-7. [PubMed: 18824766]  [MGI Ref ID J:158042]

Xia CF; Smith RS Jr; Shen B; Yang ZR; Borlongan CV; Chao L; Chao J. 2006. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47(4):752-61. [PubMed: 16534002]  [MGI Ref ID J:135763]

Xiao HD; Fuchs S; Cole JM; Disher KM; Sutliff RL; Bernstein KE. 2003. Role of bradykinin in angiotensin-converting enzyme knockout mice. Am J Physiol Heart Circ Physiol 284(6):H1969-77. [PubMed: 12637363]  [MGI Ref ID J:83894]

Yang XP; Liu YH; Mehta D; Cavasin MA; Shesely E; Xu J; Liu F; Carretero OA. 2001. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res 88(10):1072-9. [PubMed: 11375278]  [MGI Ref ID J:111458]

Yosipiv IV; Dipp S; El-Dahr SS. 2001. Targeted disruption of the bradykinin B(2) receptor gene in mice alters the ontogeny of the renin-angiotensin system. Am J Physiol Renal Physiol 281(5):F795-801. [PubMed: 11592936]  [MGI Ref ID J:72552]

Zaika O; Zhang J; Shapiro MS. 2011. Functional role of M-type (KCNQ) K(+) channels in adrenergic control of cardiomyocyte contraction rate by sympathetic neurons. J Physiol 589(Pt 10):2559-68. [PubMed: 21486761]  [MGI Ref ID J:185252]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryThis strain is maintained by homozygous sibling matings. Expected coat color from breeding:Black

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Frozen Products

Price (US dollars $)
Frozen Embryo $1650.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Frozen Products

Price (US dollars $)
Frozen Embryo $2145.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   101045 B6129SF2/J (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)